<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00293228</url>
  </required_header>
  <id_info>
    <org_study_id>137</org_study_id>
    <nct_id>NCT00293228</nct_id>
  </id_info>
  <brief_title>Treatment of Latent Tuberculosis Infection With Isoniazid</brief_title>
  <official_title>Drugs for Treatment of Latent Tuberculosis Infection Objective 4: Identify Biomarkers for Clinical Trials of Drugs Active Against Latent TB</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Salud Publica, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wellcome Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Nacional de Salud Publica, Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study the effect that treatment of dormant tuberculosis
      infection has on the immunological system.

      We expect to observe an impact over the production of cytokines by peripheral white blood
      cells which may be useful to know if treatment has been effective.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As part of on-going studies conducted in the Orizaba Health Jurisdiction in southeastern
      Mexico, household contacts of pulmonary TB patients who recently converted their tuberculin
      test and TST+ve contacts from randomly selected control households with no history of TB
      within the last 2 years (remote contacts) will be enrolled. We assume that these individuals
      are infected with Mycobacterium tuberculosis. Additional confidence that all subjects
      enrolled are latently infected will come from ELISPOT analysis of the response to ESAT-6 and
      CFP-10. We propose to administer INH to 100 TST+ve recent and 100 TST+ve remote contacts for
      6 months. To control for spontaneous fluctuations of biomarker levels, we propose to defer
      therapy by 3 months to half the subjects in each group. Thus, four groups will be defined:

      A. Recently converted contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6
      months) immediately after recruitment.

      B. Recently converted contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6
      months) three months after recruitment.

      C. Remote contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6 months)
      immediately after recruitment.

      D. Remote contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6 months) three
      months after recruitment.

      All contacts will undergo clinical evaluation at enrolment and review. The development of
      active TB will trigger withdrawal and full treatment. Fortnightly clinical review of group B
      during the deferred phase will be undertaken. ELISPOT analysis will be performed on all
      subjects at 0, 1, 4, 13, 26 and 40 weeks in groups A and C, and at 0, 13, 14, 17, 26, 40 and
      54 weeks in groups B and D. A subset of 10 patients per group will be sampled for expression
      analysis at 0, 4, 26 and 40 weeks (groups A and C) and at 0, 13, 17 and 40 weeks in groups B
      and D (160 hybridizations in total).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of Mtb antigen-specific IFNγ-producing T cells measured by ELISPOT assay</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gene expression profiling</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recently converted contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6 months) immediately after recruitment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>B. Recently converted contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6 months) three months after recruitment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>C. Remote contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6 months) immediately after recruitment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>D. Remote contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6 months) three months after recruitment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoniazid</intervention_name>
    <description>Isoniazid (5mg per kg up to 300 mg daily for 6 months)</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
    <other_name>treatment of latent tuberculosis infection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isoniazid</intervention_name>
    <description>isoniazid (5mg per kg up to 300 mg daily for 6 months</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
    <other_name>Treatment of latent tuberculosis infection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Informed consent

          -  Age 10-45

          -  Either sex

          -  Resident in study area

          -  Documented TST+ve (&gt;10mm, Mantoux method, 2TU, PPD Statens Serum Institute)

          -  Normal chest radiograph

          -  HIV negative test

        Exclusion criteria:

          -  Active tuberculosis

          -  Previous diagnosis of tuberculosis

          -  Treatment for active or latent tuberculosis

          -  Contact with TB patients harboring MDR or INH resistant isolates of Mtb

          -  Diseases or therapies associated with immunosuppression

          -  Diabetes mellitus

          -  Abnormal liver enzyme levels.

          -  HB below 8gr/dl

          -  Pregnancy (ascertained by urinary β-HCG)

          -  Allergy or intolerance to isoniazid

          -  Peripheral neuropathy

          -  Ingestion of drugs interacting with isoniazid
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lourdes Garcia-Garcia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Salud Pública</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose Sifuentes-Osornio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alfredo Ponce-de-Leon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eduardo Sada-Diaz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Enfermedades Respiratorias</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martha Torres-Rojas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Enfermedades Respiratorias</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Nacional de Salud Pública</name>
      <address>
        <city>Cuernavaca</city>
        <state>Morelos</state>
        <zip>62508</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Wilkinson KA, Kon OM, Newton SM, Meintjes G, Davidson RN, Pasvol G, Wilkinson RJ. Effect of treatment of latent tuberculosis infection on the T cell response to Mycobacterium tuberculosis antigens. J Infect Dis. 2006 Feb 1;193(3):354-9. Epub 2005 Dec 29.</citation>
    <PMID>16388482</PMID>
  </reference>
  <reference>
    <citation>DeRiemer K, García-García L, Bobadilla-del-Valle M, Palacios-Martínez M, Martínez-Gamboa A, Small PM, Sifuentes-Osornio J, Ponce-de-León A. Does DOTS work in populations with drug-resistant tuberculosis? Lancet. 2005 Apr 2-8;365(9466):1239-45.</citation>
    <PMID>15811457</PMID>
  </reference>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2006</study_first_submitted>
  <study_first_submitted_qc>February 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2006</study_first_posted>
  <last_update_submitted>May 25, 2010</last_update_submitted>
  <last_update_submitted_qc>May 25, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2010</last_update_posted>
  <responsible_party>
    <name_title>Lourdes Garcia-Garcia</name_title>
    <organization>Instituto Nacional de Salud Publica</organization>
  </responsible_party>
  <keyword>Latent tuberculosis</keyword>
  <keyword>biomarkers</keyword>
  <keyword>isoniazid</keyword>
  <keyword>ELISPOT</keyword>
  <keyword>PPD positive individuals</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Latent Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isoniazid</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 12, 2012</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>April 18, 2012</submitted>
    <returned>May 15, 2012</returned>
    <submitted>April 6, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

